Session » (1124–1154) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Date: Monday, November 13, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 1148

A Comparative Study of Clinical Phenotype in Relation to NOD2 Sub-genotypes in Yao Syndrome

9:00AM-11:00AM: Abstract Number: 1150

A Comparative Study of Cryofibrinogenemia Before and After COVID-19 Era

9:00AM-11:00AM: Abstract Number: 1124

A Double-blind, Placebo-parallel Controlled Phase III Clinical Study of the Efficacy and Safety of Hemay005 Tablets in Patients with Moderate to Severe Chronic Plaque Psoriasis in China

9:00AM-11:00AM: Abstract Number: 1142

A Retrospective Analysis of Radiographic and Serologic Findings in Patients with Scleroderma and Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1125

A Rheumatologic Clinical Profile of the VEXAS Syndrome: Results from a Survey Conducted Among Rheumatologic Units of 126 Hospitals Across Spain

9:00AM-11:00AM: Abstract Number: 1129

Accuracy and Performance Characteristics of Administrative Codes for the Diagnosis of Autoinflammatory Syndromes: A Discovery and Validation Study

9:00AM-11:00AM: Abstract Number: 1137

Association Between Nailfold Videocapillaroscopy Findings and sKL-6 Levels in Patients with Idiopathic Inflammatory Myopathies–Related Interstitial Lung Disease

9:00AM-11:00AM: Abstract Number: 1147

Blood-Based Biomarkers of Inflammation and Tissue Remodeling Can Discriminate Between Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis and Are Associated with Hand Function

9:00AM-11:00AM: Abstract Number: 1136

Challenges in Diagnosing VEXAS Syndrome: Delayed Diagnosis, Misdiagnosis, and Associations with Specific Gene Mutations

9:00AM-11:00AM: Abstract Number: 1131

Clinical Phenotypes of IgG4-related Disease in a Multi-ethnic Singapore Cohort

9:00AM-11:00AM: Abstract Number: 1154

Clinical Presentation of IgG4-Related Disease. Single Referral Hospital Experience and Literature Review

9:00AM-11:00AM: Abstract Number: 1141

COVID-19 Vaccination Status and Adverse Events Following SARS-CoV-2 Vaccine in Autoimmune Inflammatory Rheumatic Disease (AIRD) Patients: A Single Center Experience

9:00AM-11:00AM: Abstract Number: 1144

Deucravacitinib in Plaque Psoriasis: Maintenance of Response over 3 Years

9:00AM-11:00AM: Abstract Number: 1133

Exploring the Clinical Characteristics and Correlation with Corticosteroid Dependence in Polymyalgia Rheumatica (PMR) Patients: Insights from an Academic Center

9:00AM-11:00AM: Abstract Number: 1127

Factors Associated with Vision-Related Quality of Life in Patients with Non-infectious Uveitis: A Longitudinal Analysis

9:00AM-11:00AM: Abstract Number: 1139

From Skin to Bone Lesions: A Pioneer Study Unraveling the Underdiagnosis of SAPHO Syndrome in the Dominican Republic

9:00AM-11:00AM: Abstract Number: 1146

Gene X Environment Paradigm: Exemplified by Selected Cases of Autoinflammatory Diseases

9:00AM-11:00AM: Abstract Number: 1145

Human Cardiovascular Disease Model Provides Transcriptomic Evidence of Cardiovascular Risk Associated with Febuxostat

9:00AM-11:00AM: Abstract Number: 1126

Identification of Clinical Phenotypes in Behçet’s Disease Using a Cluster Analysis

9:00AM-11:00AM: Abstract Number: 1140

Inflammation Is More Prominent Than Joint Damage at Initial Visits of Patients with Inflammatory Arthritides, but Organ Damage Is More Prominent and Patient Distress Is as Prominent as Inflammation in Overall Rheumatology Care: Data from a Feasible Physician RheuMetric Checklist

9:00AM-11:00AM: Abstract Number: 1130

Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: UVEDAI

9:00AM-11:00AM: Abstract Number: 1138

Nailfold Capillaroscopy Findings in Patients with Idiopathic Inflammatory Myopathies and Its Association to Autoantibodies

9:00AM-11:00AM: Abstract Number: 1143

Nationwide Analysis of Adult-Onset Still’s Disease with and Without Hemophagocytic Lymphohistiocytosis

9:00AM-11:00AM: Abstract Number: 1134

Pilot Study Investigating Adenosine Deaminase-2 as a Disease Activity Biomarker for Cardiac Sarcoidosis

9:00AM-11:00AM: Abstract Number: 1132

Preclinical Profiles of FZ007-119, a Highly Potent and Selective Tyk2 Inhibitor, for the Treatment of Immune Mediated Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 1128

Refractory Inflammatory Ocular Pathology and Treatment with Janus Kinase Inhibitors. Multicenter Study and Literature Review

9:00AM-11:00AM: Abstract Number: 1152

Relation Between Positive MPO-ANCA Antibodies And: Associated Diseases, Anca-associated Vasculitis Specificty, Severity and Prognosis. Study from a Single University Hospital

9:00AM-11:00AM: Abstract Number: 1151

Revised IWOS Criteria for Ocular Sarcoidosis: A 2019 Review of the 2009 Criteria in a Study of 384 Patients from a Single University Hospital

9:00AM-11:00AM: Abstract Number: 1135

The Prescribing Patterns and Role of TNF-α Inhibitors in Treatment of Cardiac Sarcoidosis Patients

9:00AM-11:00AM: Abstract Number: 1149

Tumor Necrosis Factor Inhibitors as First Line Steroid-Sparing Therapy for Neurosarcoidosis: A Case Series

9:00AM-11:00AM: Abstract Number: 1153

Unmasking SAPHO: A Case Series Revealing the Clinical Spectrum and Treatment Approaches

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].